Retinal Artery Contraction After Phenylephrine as a Cardiovascular Risk Biomarker.
choroidal thickness
peripapillary choroidal thickness
phenylephrine
retinal nerve fiber layer
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
01
2020
accepted:
01
04
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
epublish
Résumé
We investigated the in vivo changes of artery diameter (AD) and vein diameter (VD) after topical phenylephrine 2.5% instillation, and its relationship with the Systematic Coronary Risk Evaluation (SCORE). This is a cross-sectional study. Healthy control patients were included. All of the participants underwent enhanced depth imaging by spectral-domain optical coherence tomography before and 30 minutes after phenylephrine instillation, using eye-tracking and follow-up software. Changes in AD and VD were assessed. The study included 45 eyes of 45 patients (14 males and 31 females). The mean age was 58.6 ± 15.1 years (26-88 years). Mean SCORE risk estimation value was 2.0 (0-14). No significant correlation was found between pre-phenylephrine AD or VD with age (p=0.237 and p=0.821, respectively), SCORE (p=0.545 and p=0.723, respectively). AD significant thinned after phenylephrine (p<0.001), whereas no significant changes could be depicted in VD (p=0.474). Changes in AD after phenylephrine were significantly related with SCORE risk estimation (p=0.035). Discordantly, changes in VD after phenylephrine were not significantly related with SCORE (p=0.505). As a significant thinning of AD occurred following phenylephrine instillation, and as the magnitude of this thinning is related with SCORE, it is useful to test the retinal artery contraction to infer the cardiovascular health status.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
We investigated the in vivo changes of artery diameter (AD) and vein diameter (VD) after topical phenylephrine 2.5% instillation, and its relationship with the Systematic Coronary Risk Evaluation (SCORE).
METHODS
METHODS
This is a cross-sectional study. Healthy control patients were included. All of the participants underwent enhanced depth imaging by spectral-domain optical coherence tomography before and 30 minutes after phenylephrine instillation, using eye-tracking and follow-up software. Changes in AD and VD were assessed.
RESULTS
RESULTS
The study included 45 eyes of 45 patients (14 males and 31 females). The mean age was 58.6 ± 15.1 years (26-88 years). Mean SCORE risk estimation value was 2.0 (0-14). No significant correlation was found between pre-phenylephrine AD or VD with age (p=0.237 and p=0.821, respectively), SCORE (p=0.545 and p=0.723, respectively). AD significant thinned after phenylephrine (p<0.001), whereas no significant changes could be depicted in VD (p=0.474). Changes in AD after phenylephrine were significantly related with SCORE risk estimation (p=0.035). Discordantly, changes in VD after phenylephrine were not significantly related with SCORE (p=0.505).
CONCLUSION
CONCLUSIONS
As a significant thinning of AD occurred following phenylephrine instillation, and as the magnitude of this thinning is related with SCORE, it is useful to test the retinal artery contraction to infer the cardiovascular health status.
Identifiants
pubmed: 32494117
doi: 10.2147/OPTH.S247680
pii: 247680
pmc: PMC7227810
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1269-1275Informations de copyright
© 2020 Casado et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Glaucoma. 2018 Aug;27(8):699-702
pubmed: 29877967
Trans Am Ophthalmol Soc. 1992;90:561-94
pubmed: 1494834
Arch Ophthalmol. 2006 Jan;124(1):87-94
pubmed: 16401789
J Biol Chem. 2010 Jun 25;285(26):19699-704
pubmed: 20410298
Br J Ophthalmol. 2003 Apr;87(4):505-6
pubmed: 12642324
Ophthalmic Physiol Opt. 2005 May;25(3):195-204
pubmed: 15854064
Eur Heart J. 2003 Jun;24(11):987-1003
pubmed: 12788299
Age (Dordr). 2013 Aug;35(4):1219-34
pubmed: 22777652
Hypertension. 2008 Jan;51(1):119-26
pubmed: 17998474
Cleve Clin J Med. 2008 Sep;75(9):663-72
pubmed: 18788227
Am J Ophthalmol. 2013 Oct;156(4):706-14
pubmed: 23876868
Trans Ophthalmol Soc U K. 1969;88:167-86
pubmed: 4989799
Am J Hypertens. 2007 Aug;20(8):846-52
pubmed: 17679031
Circulation. 2003 Nov 4;108(18):2230-5
pubmed: 14557363
PLoS One. 2014 Nov 05;9(11):e112311
pubmed: 25372785
PLoS One. 2017 Jun 23;12(6):e0179663
pubmed: 28644852
Med J Malaysia. 1994 Jun;49(2):158-63
pubmed: 8090095
Vascul Pharmacol. 2012 Sep-Oct;57(2-4):81-90
pubmed: 22172524
Stroke. 2013 Aug;44(8):2121-7
pubmed: 23715958
Retina. 2013 Oct;33(9):1888-94
pubmed: 23719399
Circulation. 2000 Apr 11;101(14):1653-9
pubmed: 10758046
Free Radic Biol Med. 2010 Aug 1;49(3):307-16
pubmed: 20388537
Eye (Lond). 1997;11 ( Pt 6):946-8
pubmed: 9537165
Clin Exp Ophthalmol. 2018 Jul;46(5):531-552
pubmed: 29193621
Am J Epidemiol. 2008 Jan 1;167(1):51-8
pubmed: 17893402
Br J Ophthalmol. 1975 Jan;59(1):3-44
pubmed: 804913
PLoS One. 2016 Sep 13;11(9):e0162468
pubmed: 27622495
Lancet Neurol. 2009 Jul;8(7):628-34
pubmed: 19481977
J Hypertens. 2001 May;19(5):921-30
pubmed: 11393676
Eye (Lond). 1998;12 ( Pt 6):973-5
pubmed: 10325999
Br J Pharmacol. 2000 Jan;129(2):381-7
pubmed: 10694246